key: cord-0876709-apmiq1nc
authors: Poyiadji, Neo; Cormier, Peter; Patel, Parth Y.; Hadied, Mohamad O.; Bhargava, Pallavi; Khanna, Kanika; Nadig, Jeffrey; Keimig, Thomas; Spizarny, David; Reeser, Nicholas; Klochko, Chad; Peterson, Edward L.; Song, Thomas
title: Acute Pulmonary Embolism and COVID-19
date: 2020-05-14
journal: Radiology
DOI: 10.1148/radiol.2020201955
sha: 6d6375bfa7afff7fcb339579736600b4f1dfadbf
doc_id: 876709
cord_uid: apmiq1nc

Risk factors for pulmonary embolism in patients with coronavirus disease 2019 include obesity, an elevated d-dimer value, elevated C-reactive protein level, and a rising d-dimer value over time.

Institutional review board approval and waived informed consent were obtained for this retrospective analysis. All chest examinations performed in a single health system across multiple hospitals from March 16, 2020, to April 18, 2020, were obtained from the picture archiving and communication system database. From this list, patients with pulmonary CT angiography were identified; those who had a positive reverse transcriptase polymerase chain reaction result on nasopharyngeal swab formed the study population (Fig 1) . The reverse transcriptase polymerase chain reaction test was developed in-house by the Clinical Microbiology Laboratory with Federal Drug Agency's Emergency Use Authorization. All pulmonary CT angiography studies were initially read by fellowship-trained thoracic or abdominal radiologists, or emergency radiologists, all with 2-40 years of experience. The radiology reports for these examinations were reviewed to determine the presence or absence of PE. CT studies that were limited by respiratory motion or poor contrast opacification were excluded. In addition, nine patients who tested positive for COVID-19 underwent two pulmonary CT angiograms during their admission, and only the most recent CT and respective laboratory values were included in data analysis. Patient charts were reviewed for demographic, laboratory, and clinical outcome variables. Laboratory values that were obtained within 2 days of the pulmonary CT angiogram were used in data analysis. If a patient was found to have a PE on a pulmonary CT angiogram performed more than 2 days after admission, then the admission values and values just prior to the CT were recorded to evaluate for absolute change. Simplified PE severity index scores were calculated based on clinical variables.

Wilcoxon two-sample test was used to analyze continuous variables and Pearson x 2 test was used for nominal variables. Logistic regression was used to generate area under the receiver operating characteristic curve estimates. Sensitivity and specificity were chosen based on values that maximized sum over all possible cut points. A forward stepwise logistic regression with an a value of .05 required for inclusion was used to determine a multivariable model. Demographic and laboratory values listed in the footnote of Table 1 were considered for inclusion. The final model included the smallest set of variables where each met the significance criteria and included hypertension, history of PE, body mass index greater than 30 kg/m 2 , statin therapy, and d-dimer value prior to pulmonary CT angiography. Odds ratios were calculated for each variable while adjusting for other variables in the multivariable model.

During a 1-month period, 328 patients with a positive reverse transcriptase polymerase chain reaction test result for COVID-19 underwent pulmonary CT angiography. Among these, 72 of 328 (22%; 95% confidence interval [CI]: 18%, 27%) were found to have a PE (Fig 1) . Demographic results are depicted in Table 2 . Patients with a body mass index greater than 30 kg/m 2 were seen more frequently in the PE group compared with the non-PE group (58% vs 44%; P = .045; see example in Fig 2) . Fewer patients with PE were undergoing statin therapy prior to admission compared with the non-PE cohort (27% vs 46%; P = .005). There was no significant difference in age, sex, ethnicity, or history of cardiopulmonary disease such as congestive heart failure or chronic obstructive pulmonary disease. Laboratory values obtained prior to pulmonary CT angiography and absolute change in laboratory values from admission to just prior to pulmonary CT angiography within 2 days are depicted in Table 2 . Mean d-dimer value, obtained within 2 days of pulmonary CT angiography, was higher in the PE positive group relative to the PE negative group (9.33 mg/mL vs 2.54 mg/ mL; P = .001). Mean C-reactive protein level, obtained within 2 days of pulmonary CT angiography, was also higher in the PE-positive group compared with the PE-negative group (10.0 mg/dL vs 7.4 mg/dL; P = .01). Oxygen requirements, measured in liters per minute in nonintubated patients within 4 hours prior to pulmonary CT angiography, was higher in the PE group than the non-PE group (4.3 L/min vs 2.7 L/min; P = .007).

In the PE group, the location of the PE was recorded with respect to the most proximal embolus. Distribution was as follows: 51% (37 of 72) segmental PE, 31% (22 of 72) lobar PE, 13% (nine of 72) central PE, and 5.5% (four of 72) subsegmental PE. CT evidence of right heart strain was documented in 11% Table 1 . Patients receiving statin therapy prior to admission had an adjusted multivariable odds ratio of 0.4 (95% CI: 0.23, 0.75; P = .005) for developing a PE. Patients with a body mass index greater than 30 kg/m 2 had an adjusted multivariable odds ratio of 2.7 (95% CI: 1.3, 5.5; P = .006) for developing a PE. An increase in d-dimer value of 6 mg/mL had an odds ratio of 4.8 (95% CI: 3.2, 7.2; P = .001) for developing a PE. The multivariable model had an area under the receiver operating characteristic curve estimate of 0.86 (95% CI: 0.81, 0.91). Sensitivity and specificity for a d-dimer value of 3.11mg/mL were 78% and 81%, respectively, for development of PE, with an area under the receiver operating characteristic curve estimate of 0.85.

Respiratory tract infection is a known risk factor in development of pulmonary embolism (PE) in hospitalized patients (4) . In recently published studies, the incidence of PE in patients with coronavirus disease 2019 (COVID-19) who underwent pulmonary CT angiography was reported to be between 23%-30%, which is similar to our rate of 22% (5,6). Our patient population is unique when compared with recently published studies. There were a greater number of African American patients and patients with obesity in our demographic distribution. In our study, patients with a body mass index greater than 30 kg/m 2 were 2.7 times more likely to develop a PE, which has not been previously described. Recent literature suggests that obesity in COVID-19 is associated with more severe disease (7) . We found that patients with COVID-19 receiving statin therapy prior to admission are less likely to develop a PE. Statins have been previously described to be associated with decreased rates of ve- nous thromboembolism, as well as decreased risk of recurrent PE (8, 9) .

In our study, we found a significant difference in C-reactive protein level and d-dimer value between PE-positive and PEnegative groups, which may suggest that patients with a positive COVID-19 test with higher levels of inflammation and d-dimer values are more susceptible to developing PE. In addition, we found that nonintubated patients who developed PE required more oxygen prior to pulmonary CT angiography evaluation than did their non-PE counterparts.

We did not find a significant difference in ICU admissions, requirement for intubation, or duration of intubation between patients who developed PE and those who did not. In fact, 72% (52 of 72) of PEs were diagnosed in patients who did not require ICU-level care. This is in sharp contrast to a recently published study (5) highlighting PE to be associated with ICU admission and mechanical ventilation. Our results suggest that even patients who do not have severe enough illness to qualify for ICU care can develop acute PE.

Limitations of our study included its retrospective nature and restriction to a single-health system.

Our study, in conjunction with recent and future studies, may prompt early evaluation with pulmonary CT angiography in patients with coronavirus disease 2019 who are at increased risk for developing pulmonary embolism based on demographic, clinical, and laboratory variables (6, 7, 10) . 

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Review: Viral infections and mechanisms of thrombosis and bleeding

Acute infection as a trigger for incident venous thromboembolism: Results from a population-based case-crossover study

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Statins as a preventative therapy for venous thromboembolism

Statin treatment and the risk of recurrent pulmonary embolism

Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands